Is covalently crosslinked Aβ responsible for synaptotoxicity in Alzheimer's disease?

Current Alzheimer Research

Volumn 5, Issue 6, 2008, Pages 533-539

  Naylor, R ^a,b   Hill, A F ^a,b   Barnham, K J ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

A ; Beta amyloid; Covalent crosslinks; Metal; Neurotoxicity; Oligomer; Synaptotoxicity

Indexed keywords

AMYLOID BETA PROTEIN; METAL ION; OLIGOMER; CROSS LINKING REAGENT;

ALZHEIMER DISEASE; CHEMICAL REACTION; CROSS LINKING; DISEASE COURSE; HUMAN; METAL BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; REVIEW; SYNAPTOTOXICITY; TOXICITY; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; SYNAPSE;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN; ANIMALS; CROSS-LINKING REAGENTS; HUMANS; MOLECULAR SEQUENCE DATA; SYNAPSES;

EID: 58049203021     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720508786898433     Document Type: Review

References (80)

1. Small DH. Recent findings on the biology of Alzheimer's disease. Res Pract Alzheimer's Dis 3: 27-33 (2000).
2. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155: 853-862 (1999).
3. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46: 860-866 (1999).
4. Atwood CS, Perry G, Zeng H, Kato Y, Jones WD, Ling K, et al. Copper Mediates Dityrosine Cross-Linking of Alzheimer's Amyloid-β. Biochemistry 43: 560-568 (2004).
5. Barnham KJ, Haeffner F, Ciccotosto GD, Curtain CC, Tew D, Mavros C, et al. Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J 18: 1427-1429 (2004).
6. Webber KM, Casadesus G, Atwood CS, Bowen RL, Perry G, Smith MA, et al. Gonadotropins: A cohesive gender-based etiology of Alzheimer disease. Mol Cell Endocrinol 260-262: 271-275 (2007).
7. Maurer K, Hoyer S. Alois Alzheimer revisited: differences in origin of the disease carrying his name. J Neural Transm 113: 1645-1658 (2006).
8. Lee H, Zhu X, Castellani RJ, Nunomura A, Perry G, Smith MA, et al. Amyloid-beta in Alzheimer Disease: The Null versus the Alternate Hypothesis. J Pharmacol Exp Ther 321: 823-9 (2007).
9. Harigaya Y, Saido TC, Eckman CB, Prada CM, Shoji M, Younkin SG, et al. Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochem Biophys Res Commun 276: 422-427 (2000).
10. Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature 443: 768-773 (2006).
11. Bellizzi MJ, Lu SM, Gelbard HA. Protecting the synapse: evidence for a rational strategy to treat HIV-1 associated neurologic disease. J Neuroimmune Pharmacol 1: 20-31 (2006).
12. Mattson MP, Partin J, Begley JG. Evidence for synaptic apoptosis. Exp Neurol 153: 35-48 (1998).
13. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 281: 1401-1406 (1999).
14. Tiraboschi P, Hansen LA, Alford M, Masliah E, Thal LJ, Corey-Bloom, J, et al. The decline of synapses and cholinergic activity is asynchronous in Alzheimer's disease. Neurology 55: 1278-1283 (2000).
15. Hawkes CA, McLaurin J. Immunotherapy as treatment for Alzheimer's disease. Expert Rev Neurother 7: 1535-1548 (2007).
16. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci USA 103: 5644-5651 (2006).
17. Harigaya Y, Shoji M, Shirao T, Hirai S. Disappearance of actin-binding protein, drebrin, from hippocampal synapses in Alzheimer's disease. J Neurosci Res 43: 87-92 (1996).
18. Gylys KH, Fein JA, Yang F, Wiley DJ, Miller CA, Cole GM, et al. Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. Am J Pathol 165: 1809-1817 (2004).
19. Yao PJ, Zhu M, Pyun EI, Brooks AI, Therianos S, Meyers VE, et al. Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease. Neurobiol Dis 12: 97-109 (2003).
20. Kelly BL, Ferreira A. Beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons. J Biol Chem 281: 28079-28089 (2006).
21. Ciccotosto GD, Tew D, Curtain CC, Smith D, Carrington D, Masters CL, et al. Enhanced toxicity and cellular binding of a modified amyloid β peptide with a methionine to valine substitution. J Biol Chem 279: 42528-42534 (2004).
22. Hensley K, Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RA, et al. Electrochemical analysis of protein nitrotyrosine and dity-rosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci 18: 8126-8132 (1998).
23. Arispe N, Rojas E, Polard HB. Alzheimer Disease Amyloid β Protein forms Calcium Channels in Bilayer Membranes: Blockade by Tromethamine and Aluminium. Proc Natl Acad Sci USA 90: 567-571 (1993).
24. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG, et al. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 280: 17294-300 (2005).
25. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH, et al. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15: 1437-1449 (2006).
26. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48: 913-922 (2005).
27. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, et al. APP processing and synaptic function. Neuron 37: 925-937 (2003).
28. Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, et al. Endocytosis is required for synaptic activity-dependent release of Amyloid-β in vivo. Neuron 58: 42-51 (2008).
29. Selkoe DJ. The ups and downs of Aβ. Nat Med 7: 758-759 (2006).
30. Walsh DM, Townsend M, Podlisny MB, Shankar GM, Fadeeva JV, El Agnaf O, et al. Certain inhibitors of synthetic amyloid beta-peptide (Aβ) fibrillogenesis block oligomerization of natural Aβ and thereby rescue long-term potentiation. J Neurosci 25: 2455-2462 (2005).
31. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A. Opposing activities protect against age-onset proteotoxicity. Science 313: 1604-1610 (2006).
32. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 572: 477-492 (2006).
33. Wu Y, Wu Z, Butko P, Christen Y, Lambert MP, Klein WL, et al. Amyloid beta-induced pathological behaviors are suppressed by Gingko biloba extract EGb 761 and ginkolides in transgenic Caenorhabditis elegans. J Neurosci 26: 13102-13113 (2006).
34. Lambert MP, Barlow AK, Chromy BA, Edwards C, Fred R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95: 6448-6453 (1998).
35. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amylid-beta protein assembly in the brain impairs memory. Nature 440: 352-357 (2006).
36. Deshpande A, Mina E, Glabe CG, Busciglio J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci 26: 6011-6018 (2006).
37. Petkova AT, Leapman RD, Guo Z, Yau W, Mattson MP, Tycko R, et al. Self-Propagating, Molecular-Level Polymorphism in Alzheimer's β-Amyloid Fibrils. Science 307: 262-265 (2005).
38. Xu Y, Shen J, Luo X, Zhu W, Chen K, Ma J, et al. Conformational Transition of Amyloid β-peptide. Proc Natl Acad Sci USA 102: 5403-5407 (2005).
39. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313: 1781-1784 (2006).
40. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, et al. AMPAR removal underlies Aβ-induced synaptic depression and dendritic spine loss. Neuron 52: 831-843 (2006).
41. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55: 697-711 (2007).
42. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL, et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27: 2866-2875 (2007).
43. Snyder EM, Nong Y, Almeida CG, Paul SM, Moran T, Choi EY, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8: 1051-1058 (2005).
44. Spires-Jones TL, Meyer-Luehmann M, Osetek JD, Jones PB, Stern EA, Bacskai BJ, et al. Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. Am J Pathol 171: 1304-1311 (2007).
45. Nomura I, Kato N, Kita T, Takechi H. Mechanism of impairment of long-term potentiation by amyloid beta is independent of NMDA receptors or voltage-dependent calcium channels in hippocampal CA1 pyramidal neurons. Neurosci Lett 391: 1-6 (2005).
46. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturaly secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539 (2002).
47. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD, et al. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 21: 4125-4133 (2001).
48. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB, et al. Beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 275: 5626-5632 (2000).
49. Townsend M, Mehta T, Selkoe DJ. Soluble Aβ inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 282: 33305-12 (2007).
50. Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W, Martins R, et al. Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 22: RC221 (2002).
51. Huang HM, Gibson GE. Altered beta-adrenergic receptor-stimulated cAMP formation in cultured skin fibroblasts from Alzheimer donors. J Biol Chem 268: 14616-21 (1993).
52. Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 24: 3370-3378 (2004).
53. Origlia N, Righi M, Capsoni S, Cattaneo A, Fang F, Stern DM, et al. Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-β-mediated cortical synaptic dysfunction. J Neurosci 28: 3521-3530 (2008).
54. Nimmrich V, Grimm C, Draguhn A, Barghorn S, Lehmann A, Schoemaker H, et al. Amyloid β Oligomers (Aβ1-42 globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J Neurosci 28: 788-797 (2008).
55. Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, et al. Amyloid β protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci 28: 4231-4237 (2008).
56. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 39: 10831-10839 (2000).
57. Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB, et al. Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem 270: 9564-9570 (1995).
58. Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, Fairlie DP, et al. Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem 75: 1219-1233 (2000).
59. Maynard CJ, Bush AI, Masters CL, Cappai R, Li QX. Metals and amyloid-beta in Alzheimer's disease. Int J Exp Pathol 86: 147-159 (2005).
60. Cherny R, Legg JT, McLean CA, Fairlie DP, Huang X, Atwood CS, et al. Aqueous dissolution of Alzheimer's disease Abeta amyloid depositis by biometal depletion. J Biol Chem 274: 232223-232228 (1999).
61. Bitan G, Tarus B, Vollers SS, Lashuel HA, Condron MM, Straub JE, et al. A molecular switch in amyloid assembly: Met35 and amyloid beta-protein oligomerisation. J Am Chem Soc 125: 15359-15365 (2003).
62. Schaefer S, Pajonk FG, Multhaup G, Bayer TA. Copper and clioquinol treatment in young APP transgenic and wild-type mice: effects on life expectancy, body weight, and metal-ion levels. J Mol Med 85: 405-413 (2007).
63. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30: 665-676 (2001).
64. Ibach B, Haen E, Marienhagen J, Hajak G. Clioquinol treatment in familiar early onset of Alzheimer's disease: a case report. Pharmacopsychiatry 38: 178-179 (2005).
65. Okeley NM, van der Donk WA. Novel cofactors via post-translational modifications of enzyme active sites. Chem Biol 7: R159-171 (2000).
66. Wang DS, Uchikado H, Bennett DA, Schneider JA, Mufson EJ, Wu J, et al. Cognitive performance correlates with cortical isopeptide immunoreactivity as well as Alzheimer type pathology. J Alzheimers Dis 13: 53-66 (2008).
67. Ho GJ, Gregory EJ, Smirnova IV, Zoubine MN, Festoff BW. Cross-linking of beta-amyloid precursor catalyzed by tissue transglutaminase. FEBS Lett 349: 151-154 (1994).
68. Nemes Z, Fesus L, Egerhazi A, Keszthelyi A, IM D. N(epsilon) (gamma-glutamyl)lysine in cerebrospinal fluid marks Alzheimer type and vascular dementia. Neurobiol Aging 22: 403-406 (2001).
69. Citron BA, Suo Z, SantaCruz K, Davies PJA, Qin F, Festoff BW, et al. Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration. Neurochem Int 40: 69-78 (2002).
70. Zhao G, Tan J, Mao G, Cui MZ, Xu X. The same γ-secretase accounts for the multiple intramembrane cleavages of APP. J Neurochem 100: 1234-1246 (2007).
71. Tucker HM, Kihiko M, Caldwell JN, Wright S, Kawarabayashi T, Price D, et al. The plasmin system is induced by and degrades amyloid-beta aggregates. J Neurosci 20: 3937-3946 (2000).
72. Eckman EA, Reed DK, Eckman CB. Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. J Biol Chem 276: 24540-24548 (2001).
73. Howell S, Nalbantoglu J, Crine P. Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism. Peptides 16: 647-652 (1995).
74. Hu J, Igarashi A, Kamata M, Nakagawa H. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 276: 47863-47868 (2001).
75. Backstrom JR, Lim GP, Cullen MJ, Tokes ZA. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J Neurosci 16: 7910-7919 (1996).
76. Mukherjee A, Song E, Kihiko-Ehmann M, Goodman JPJ, Pyrek JS, Estus S, et al. Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques. J Neurosci 20: 8745-8749 (2000).
77. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 97: 395-406 (1999).
78. Higaki J, Catalano R, Guzzetta AW, Quon D, Nave JF, Tarnus C, et al. Processing of β-amyloid precursor protein by cathepsin D. J Biol Chem 271: 31885-31893 (1996).
79. Austen BM, Frears ER, Davies H. The use of SELDI ProteinChip (TM) arrays to monitor production of Alzheimer's β-amyloid in transfected cells. J Peptide Sci 6: 459-469 (2000).
80. Chen F, Yang D, Petanceska S, Yang A, Tandon A, Yu G, et al. Carboxyl-terminal fragments of Alzheimer beta-amyloid precursor protein accumulate in restricted and unpredicted intracellular compartments in presenilin 1-deficient cells. J Biol Chem 275: 36794-36802 (2000).